ArticleESMO real world data and digital oncology2026
Comprehensive, near real-time national systemic anti-cancer therapy (SACT) data: descriptive study of implementation and applications in Scotland (UK) from 2014.
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemotherapy Electronic Prescribing and Administration Systems (CEPAS) in Scotland support safe prescription and administration of systemic anti-cancer therapy (SACT), with instances set up according to local processes and governance criteria in each of the five cancer centres. We sought to create a national SACT dataset (nSACTd) standardising this information, allowing population-level analysis of activity, prescribing trends, patient safety and outcomes. Materials and methods: SACT data from five cancer centres, covering all hospital-prescribed SACT for adult patients in National Health Service Scotland, were brought into Public Health Scotland through a weekly data connection, resulting in separate records for every dose administered, linking to other national datasets and the latest reference information at the time of appointment using a unique personal identifier. Data feeds were adapted for regional differences in recording using national mapping tables and derivations to standardise and prepare data for analysis. Results: The nSACTd contains standardised population-level information on >2.2 million SACT appointments, detailing ∼300 000 treatments in 144 000 patients, covering both solid tumours and haematological malignancies since 2014. It provides valuable, timely information being utilised for monitoring, service planning and research purposes. Initial uses highlighted the ever-increasing demand for SACT and the impact of coronavirus disease 2019 on regimen routes. Conclusions: The Scottish nSACTd is a globally unique, comprehensive population-based data collection of SACT information. National mapping tables and algorithms provide a robust method of bringing together separately managed CEPAS into one data platform. Many applications of the nSACTd have been undertaken, and development continues to explore full utilisation of these valuable data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.